Stifel lowered the firm’s price target on RXO Inc. (RXO) to $15 from $17 and keeps a Hold rating on the shares. The company reported disappointing Q3 results, missing on most major financial metrics, the analyst tells investors in a research note. The firm added that it believes disappointing guidance and anticipated gross margin pressure in a tightening spot rate environment will be meaningful headwinds to that progress.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO Inc. price target lowered to $10 from $11 at Susquehanna
- RXO Inc. price target lowered to $15 from $17 at UBS
- RXO Inc. price target lowered to $15 from $17 at Barclays
- RXO, Inc. Reports Q3 2025 Financial Results
- RXO, Inc. Hold Rating: Challenging Market Conditions and Margin Pressures Impact Outlook